Table 44Tranexamic acid versus standard treatment

OutcomesNo. of Participants
(studies)
Follow up
Quality of the evidence
(GRADE)
Relative effect
(95% CI)
Anticipated absolute effects
Risk with placebo - low risk - adultsRisk difference with TXA (95% CI)
No. of patients receiving allogeneic transfusions (route)626
(4 studies)
VERY LOWa,b
due to risk of bias, imprecision
RR 0.83
(0.3 to 2.29)
Study population
23 per 10004 fewer per 1000
(from 16 fewer to 29 more)
No. of patients receiving allogeneic transfusions (route) - Topical TXA400
(1 study)
VERY LOWa,b
due to risk of bias, imprecision
RR 0.2
(0.01 to 4.14)
Study population
10 per 10008 fewer per 1000
(from 10 fewer to 31 more)
No. of patients receiving allogeneic transfusions (route) - Oral TXA136
(1 study)
VERY LOWa,b
due to risk of bias, imprecision
RR 1.13
(0.36 to 3.53)
Study population
76 per 100010 more per 1000
(from 48 fewer to 192 more)
Blood loss (type of surgery-topical TXA)) -Orthognathic surgery0
(1 study)
MODERATEa
due to risk of bias
The mean blood loss (type of surgery-topical TXA) -orthognathic surgery in the intervention groups was 0.93 higher
(0.73 to 1.2 higher)
Blood loss (type of surgery-topical TXA) - otolaryngeal surgery0
(2 studies)
The mean blood loss (type of surgery-topical TXA) - otolaryngeal surgery in the intervention groups was 0.74 higher
(0.73 to 0.76 higher)
a

Majority of the evidence was at high risk of bias.

b

Confidence interval crosses both MIDs.

From: 6, Alternatives to blood transfusion for patients having surgery: Cell salvage and tranexamic acid

Cover of Blood Transfusion
Blood Transfusion.
NICE Guideline, No. 24.
National Clinical Guideline Centre (UK).
Copyright © 2015 National Clinical Guideline Centre.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.